Compare MRBK & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRBK | TLSI |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.9M | 270.2M |
| IPO Year | 2018 | N/A |
| Metric | MRBK | TLSI |
|---|---|---|
| Price | $19.94 | $4.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $20.75 | $7.00 |
| AVG Volume (30 Days) | 94.9K | ★ 315.3K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 30.34 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $6,316,000.00 | N/A |
| Revenue This Year | $25.40 | $35.45 |
| Revenue Next Year | $8.15 | $37.58 |
| P/E Ratio | $115.00 | ★ N/A |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $11.87 | $2.20 |
| 52 Week High | $21.59 | $7.95 |
| Indicator | MRBK | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 58.37 |
| Support Level | $18.32 | $3.70 |
| Resistance Level | $20.74 | $4.50 |
| Average True Range (ATR) | 0.58 | 0.35 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 76.02 | 77.57 |
Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.